Accuray (ARAY) vs Baird Medical Investment (BDMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Accuray (ARAY) has outperformed Baird Medical Investment (BDMD) over the past year, gaining 97.6% versus a loss of 93.6%. Accuray is the larger company by market cap ($6.2 million vs $5.1 million), about 1.2 times the size. Accuray converts more of its revenue into profit, with a net margin of -12.2% versus -121.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARAY | BDMD |
|---|---|---|
| Share price | $2.08 | $0.0897 |
| Market cap | $6.22M | $5.07M |
| 1-day change | -2.12% | -12.91% |
| YTD return | +153.05% | -93.40% |
| 1-year return | +97.62% | -93.64% |
| 5-year return | -59.47% | — |
| Forward P/E | — | 0.64 |
| EPS (TTM) | $-5.60 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $401.95M | $22.54M |
| Revenue growth (YoY) | -12.34% | -39.15% |
| Net income (latest FY) | $-49.19M | $-27.28M |
| Gross margin | 27.73% | 83.79% |
| Operating margin | -6.58% | -113.73% |
| Net margin | -12.24% | -121.04% |
| 52-week high | $45.20 | $3.70 |
| 52-week low | $2.05 | $0.073 |
| Distance from 52-week high | -95.41% | -97.58% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +4359.31% |
| Average volume | 201.35K | 16.31M |
| Shares outstanding | 3.00M | 56.52M |
| Employees | 809 | 146 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARAY has outperformed BDMD by 191.3 percentage points over the past year.
- Accuray is more profitable, keeping -12.2 cents of every revenue dollar as net income versus -121.0 cents for Baird Medical Investment.
- Accuray grew revenue faster in its latest fiscal year (-12.34% vs -39.15%).
About Accuray
ARAY stock →Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Health Care · Medical/Dental Instruments · 809 employees
About Baird Medical Investment
BDMD stock →Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation.
Health Care · Medical/Dental Instruments · 146 employees
ARAY vs BDMD FAQ
Which is bigger, Accuray or Baird Medical Investment?
Accuray (ARAY) is larger, with a market capitalization of $6.22M compared with $5.07M for Baird Medical Investment (BDMD).
Which stock has performed better over the past year, ARAY or BDMD?
ARAY returned +97.62% over the past 12 months, compared with -93.64% for BDMD (price return, excluding dividends). Past performance does not predict future results.
Are Accuray and Baird Medical Investment in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.